Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Fortvita Biologics (Singapore) Pte. Ltd. currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This 1 pending office action is assigned to 1 distinct examiner, CLAIRE M KAUFMAN, and is being prosecuted within 1 distinct art unit. This concentration indicates that the company's current efforts in the biotechnology sector are focused on a specific technical niche that falls under a single administrative classification.
CLAIRE M KAUFMAN is the busiest examiner for this entity, as she is responsible for the 1 pending office action currently active. Because there is only 1 distinct examiner involved, the company's immediate success in obtaining patent protection is entirely dependent on this individual's interpretation of the claims. The presence of only 1 distinct art unit means that the prosecution is subject to the specific procedural guidelines and prior art databases used by that particular division.
For a practitioner, this data suggests a highly centralized prosecution environment with no room for comparing examiner behavior across multiple applications. The strategy for Fortvita Biologics (Singapore) Pte. Ltd. is currently tied to the specific tendencies of CLAIRE M KAUFMAN. With only 1 pending office action, the company does not have a diversified portfolio of active matters to mitigate the risk of a single unfavorable examiner decision.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KAUFMAN, CLAIRE M | 1 | 63.3% | +51.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18246939 | ANTI-CLAUDIN18.2 AND CD3 BISPECIFIC ANTIBODY AND USE THEREOF | KAUFMAN, CLAIRE M | 21d |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18246939 | ANTI-CLAUDIN18.2 AND CD3 BISPECIFIC ANTIBODY AND USE THEREOF | KAUFMAN, CLAIRE M | 1674 | §112Other | Non-Final OA | 21d | Pending | Mar 28, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialFortvita Biologics (Singapore) Pte. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Claire M Kaufman has the most, with 1 of Fortvita Biologics (Singapore) Pte. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
